Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

March 4, 2022 11:09 AM ESTUpdated 05:12 PM

In new research paper, Novartis outlines how an old SMA program could alter the course of Huntington's

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges